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Background: Co-infection with malaria and other infectious diseases has been shown to increase viral load
and accelerate HIV disease progression. A recent study in Kenya demonstrated that providing long-lasting
insecticide-treated bednets (LLIN) and water filters (WF) to HIV-positive adults with CD4 350 cells/mm3
significantly reduced HIV progression.
Design: We conducted a cost analysis to estimate the potential net financial savings gained by delaying
HIV progression and increasing the time to antiretroviral therapy (ART) eligibility through delivering LLIN
and WF to 10% of HIV-positive adults with CD4 350 cells/mm3 in Kenya.
Results: Given a 3-year duration of intervention benefit, intervention unit cost of US$32 and patient-year
ART cost of US$757 (2011 US$), over the lifetime of ART patients, in Kenya, we estimated the intervention
could yield a return on investment (ROI) of 11 (95% uncertainty range [UR]: 523), based on a cost of about
US$2 million and savings in ART costs of about US$26 million (95% UR: 850) (discounted at 3%). Our
findings were subjected to a number of sensitivity analyses. Of note, deferral of time to ART eligibility could
potentially result in 3,000 new HIV infections not averted by ART and thus decrease ART cost savings to
US$14 million, decreasing the ROI to 6.
Conclusions: Provision of LLIN and WF could be a cost-saving and practical method to defer time to ART
eligibility in the context of highly resource-constrained environments experiencing donor fatigue for HIV/
AIDS programs.
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M
ore than two-thirds of the world’s individuals
living with HIV reside in sub-Saharan Africa.
About half of these 25 million individuals do
not yet meet World Health Organization (WHO) ‘prior-
ity’ eligibility criteria to initiate antiretroviral therapy
(ART), specified as having a CD4 count of 350 cells/mm3
or less, and among those that do meet these ‘priority’
criteria, about 70% are receiving ART (1, 2).
International development assistance for health has
grown dramatically (from $5.7 billion in 1990 to $28.1
billion in 2012) (3), and with the support of initiatives
such as the Global Fund to Fight AIDS, Tuberculosis
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and Malaria and the United States President’s Emer-
gency Plan for AIDS Relief (PEPFAR), funding specifi-
cally for HIV/AIDS has also increased (from $0.7 billion
in 2000 to $6.8 billion in 2010) (3). As a result, the
number of individuals in low- and middle-income coun-
tries receiving ART has grown from an estimated 300,000
people in 2002 to approximately 10 million in 2012 (1).
Despite these massive investments, the projected costs
of supporting ART in the coming decades will rapidly
outpace projected funding. The aids2031 Costs and
Financing Project (4) estimates global funding needs
ranging from $400 to $700 billion for 20092031, with
funding needs for low- and middle-income countries
nearing $40 billion annually by 2031  three times the
current level (5, 6). Therefore, the cost of universal, life-
long access to ART appears unsustainable given the
current funding climate (7). In addition, development
assistance for HIV/AIDS has flattened after years of steep
rises, leading to an even greater need for implementing
cost-effective interventions in highly resource-constrained
environments (8).
Interventions that can delay HIV disease progression
can moderate the growing demand for ART and result
in considerable ART-related savings. Such interventions
can free financial and human resources to be directed
both toward HIV prevention programs and treatment for
individuals with advanced disease. A recent study in Kenya
demonstrated that providing a long-lasting insecticide-
treated bednet (LLIN) and a point-of-use water filter
(WF) to HIV-positive adults not yet on ART delayed
progression of HIV disease (9). Specifically, after 2 years of
follow-up and after controlling for baseline CD4 count,
those individuals having received LLIN and WF were
27% less likely to reach the endpoint of a CD4 count
B350 cells/mm3 (HR: 0.73, p0.02) than those not
having received LLIN and WF; rate of CD4 decline was
also significantly less in the intervention group (54 cells/
mm3/year vs. 70 cells/mm3/year, p0.03) (9). In addi-
tion, the provision of LLIN and WF, in the context of
this study and when part of an integrated prevention
campaign including HIV counseling and testing, has been
shown to be highly cost-effective (10, 11).
In addition to the cost savings associated with a defer-
ral of time to ART eligibility, these interventions dir-
ectly target several other important infectious diseases
endemic to sub-Saharan Africa, including diarrhea and
malaria (12, 13). Across sub-Saharan Africa in 2010,
diarrhea and malaria accounted for more than 80,000
and 190,000 deaths among adults aged 1549 years, res-
pectively (14). Regardless of their effect on HIV progres-
sion, LLIN and WF are essential tools that would benefit
all individuals living in settings where diarrhea and
malaria are common, with greatest benefit among indi-
viduals living with HIV who are at increased risk for
diarrhea and malaria (1519).
In settings with endemic malaria and non-potable
water, common in sub-Saharan African countries, LLIN
and WF are valuable interventions for most households.
In particular, LLIN and WF given to HIV-positive in-
dividuals awaiting ART eligibility can prevent malaria
and diarrhea infections among these individuals and
their household members. Moreover, the provision of
these interventions can delay HIV progression in this
population, moderate the growing demand for ART, and
subsequently decrease ART-related costs by deferring
time to ART eligibility.
In this article, we used the findings of the Kenya study
(9) to estimate the prospective ART-related cost savings
when HIV-positive individuals not yet eligible for ART
[CD4 count 350 cells/mm3 according to WHO ‘priority’
eligibility criteria (2)] are given LLIN and WF, in Kenya.
This article does not argue for prioritization of LLIN-WF
to HIV-positive individuals as opposed to the general
population, or against ART initiation for those indivi-
duals with CD4 count 350 cells/mm3. Rather, due to the
growing demand for ART and the realities of funding
constraints, we acknowledge that most individuals will
not start ART before reaching a CD4 of 350. We focus
our analysis accordingly on the financial benefits of pro-
viding LLIN-WF to this population compared with the
status quo of no ART treatment before CD4 350.
Methods
We estimated total costs and ART cost savings for the
provision of LLIN and WF to 10%1 of HIV-positive
adults (15 years and above) awaiting ART eligibility,2
aware of their HIV status, in Kenya. The ART cost savings
were estimated over a lifetime horizon, over the lifetime
of HIV-positive individuals. The mean lifetime on ART
was assumed to be 33 years when individuals initiated
ART at a CD4 count of 350 cells/mm3 [average between a
Ugandan estimate (20) and a South African estimate (21)],
and it was assumed to be the same for all adults. Our
analysis focused on ART cost savings, that is, on how ART
costs may be deferred (discounted) in time and bring net
financial savings. The costs were discounted using a 3%
discount rate consistently with cost-effectiveness guide-
lines (22, 23). Note that likely small increases in back-
ground mortality due to deferral of ART initiation were
neglected. The duration of intervention benefit is assumed
to be Tint3 years; that is, LLIN and WF are assumed
to be effective for 3 years [Vestergaard-Frandsen personal
communication; Ref. (24)]. This analysis was performed
1Ten percent is meant to capture a conservative coverage estimate
achievable by country health systems.
2ART eligibility is defined here as a CD4 count of 350 cells/mm3 or
less: these are the individuals to prioritize for ART initiation, as
indicated by WHO [2].
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from the perspective of the healthcare provider. All costs
were reported in 2011 US dollars.
Data
We utilized the findings from the multisite Kenya trial (9).
The trial followed two prospective cohorts comprising
589 ART-naı¨ve HIV-1-positive adults from HIV clinics
at two sites in Western Kenya. Individuals enrolled in the
intervention cohort received a LLIN and a WF. Indi-
viduals in the control cohort did not receive a LLIN or
a WF. Individuals in the intervention cohort had a mean
CD4 count at enrollment of 530 cells/mm3 (IQR: 450
670) as opposed to 550 cells/mm3 (IQR: 440690) in the
control cohort. After 2 years, individuals in the interven-
tion cohort were 27% less likely to reach the endpoint
of a CD4 count B 350 cells/mm3, after controlling for
baseline CD4 count.
The subsequent relative effectiveness, Deff27%, of
delaying HIV progression was retained as the base
case for Kenya. The effectiveness might be indeed higher/
smaller in each province of Kenya. However, in lieu
of this simpler generalization, we had no empirical data
to inform a potential extrapolation of effectiveness to
each Kenyan province. We addressed limitations pertain-
ing to this assumption in the sensitivity analyses, where a
substantial (950%) variation in the key input parameters
was implemented to clearly identify the main drivers of
the results.
The number of adults that were HIV-positive and
the number of adults that were on ART was sourced
from UNAIDS (1). The LLIN-WF intervention cost was
set at cintUS$32 per person per campaign, using recently
published estimates (25) for an integrated campaign im-
plemented in Kenya (a different setting than the trial
setting). This estimate is the projected unit cost of a scaled-
up replication of the Kenya campaign as would be applied
to HIV-positive individuals who are not yet eligible for
ART. The US$32 per person cost includes US$6 for the
malaria intervention (LLIN and staff training) and US$16
for the diarrhea intervention (WF and staff training).
Though we assumed LLIN-WF to be provided to HIV-
positive individuals aware of their HIV status, the addi-
tional costs for HIV testing (test kits, counseling, condoms,
and CD4 testing) were included, that is, US$10 (25).
The annual cost per patient for ART and associated
HIV care was assumed to be cARTUS$757. The figure
of $757 per person-year of ART is the authors’ construc-
tion as this data was not available for Kenya. This is
an average cost figure derived from the cost figures
reported for low-income countries (Benin, Ethiopia, Haiti,
Uganda) from a recent review article (26), combined
with recently published cost estimates for Ethiopia and
Uganda from two PEPFAR-supported country programs
(27), and from cost estimates for rural Uganda and the
average cost for 45 sites in Zambia, extracted from two
additional publications (28, 29). The cost figures derived
from Ga´larraga et al. (26) were reported in 2009 US$
after foreign currency conversion using average annual
exchange rates and adjustment for inflation using the US
consumer price index (CPI) by the authors. We further
adjusted these figures to 2011 US$ using the US CPI. The
cost figures from Menzies et al. (27), Marseille et al. (28)
and Marseille et al. (29) all reported in US$ were similarly
adjusted to 2011 US$ using the US CPI.
All costs used were reported in 2011 US$. We
varied the cost of ART per person-year in the sensitivity
analyses.
Approach
The LLIN-WF intervention targets Nadults adults. The
total cost of the intervention would be TCintNadultscint,
and the total savings in ART care would be TCART,A.
TCART,A depends on the following inputs: Nadults, cART,
lART, Deff, v1, Tint, CD4st, and r. Notably lART is the life-
time on ART; Deff is the effectiveness; v1 is the rate
of decline of CD4 count for the group of HIV-positive
individuals not yet on ART not receiving LLIN-WF,
that is, 70 cells/mm3/year (9); Tint is the effectiveness
duration (3 years here); CD4st is the CD4 count in the
HIV-positive adult population at time of LLIN-WF
provision; and r is the annual discount rate [chosen to
be 3% (22, 23)]. A ‘return on investment’ (ROI) for the
intervention can then be defined as follows: ROI ¼ TCART ;A
TCInt
.
Further details on how TCART,A was derived are given
in the Supplementary file (Section 1).
First, we present the ROI for the base case and
examine how it varies with key parameters (cART, Deff,
lART, CD4st). Second, we report on Kenya-specific results.
All key parameter base case values used in the analysis
are listed in Table 1.
Sensitivity analysis
We assessed the robustness of our findings using both
univariate and multivariate sensitivity analysis. First,
a multivariate sensitivity analysis was conducted using
Monte Carlo simulations (n100,000 trials) where all
key parameters (Deff, cART, cint, % of HIV-positive indivi-
duals with CD4350 receiving the intervention, lART,
CD4st) were varied simultaneously. Parameter uncertainty
was included through sampling n values for each para-
meter to which was assigned either a Gamma or Beta
distribution built on each input’s mean and standard
deviation (30), resulting in n samples. Finally, extracting
the 2.5 and 97.5 percentiles allowed the determination of
95% uncertainty ranges (URs), which are reported with
the results. Further details are given in the Supplementary
file (Section 3.1).
Second, univariate sensitivity analyses were performed
including: 1) to seek the smallest cART value for which
ROI1 and 2) to seek the smallest Deff value for which
ROI1.
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In addition, we estimated the number of new HIV
infections not averted by ART which could be attributed
to deferring time to ART eligibility for those who received
LLIN and WF, assuming 0.05 infections per person-year
not on ART (31) (an extreme upper bound given that
individuals are in HIV care and receive HIV counseling
and condoms). Expected lifetime ART costs correspond-
ing to these additional infections were deducted from the
estimated ART cost savings of the campaign, in order to
highlight the worst-case scenario. Further detail is given
in the Supplementary file (Section 3.2).
All analyses were conducted using R (www.r-project.
org) and Mathematica (Wolfram Research, Inc., Math-
ematica, Version 8.0, Champaign, IL, 2010).
Results
Given a 3-year duration of intervention benefit, inter-
vention effectiveness of 27%, intervention unit cost of
US$32, patient-year cost of ART of US$757, and
CD4st500 cells/mm
3 (Table 1), we estimated an ROI
of 11.1 (95% UR: 4.722.7) (Table 2). When effectiveness
is assumed at half that found in the Kenya trial (13.5%),
the ROI would decrease to 4.7; when effectiveness is 50%
higher (40.5%), the ROI would increase to 17.1. When
the annual ART cost per patient is assumed at half that
previously assumed (US$379), the ROI would decrease
to 5.5; when annual ART cost per patient is 50% higher,
the ROI would increase to 16.6. When CD4st400 cells/
mm3, the ROI would decrease to 3.9; when CD4st530
cells/mm3 (as observed in the trial), the ROI would slightly
increase to 11.3. When lifetime on ART is assumed at
half that in the base case (16.5 years), the ROI would be
7.1 (Table 2). Finally, ROI1 until the effectiveness of
delaying HIV progression decreases to Deff 3% and the
Table 1. Key base case inputs used in the analysis of the intervention providing bednets and water filters to HIV-positive adults
to delay HIV disease progression in Kenya
Input Value Source
Duration of intervention
effectiveness Tint
3 years Vestergaard-Frandsen personal communication;
Clasen et al. (24)
Intervention cost per person
cint
$32 Kahn et al. (25)
Annual ART cost per patient
cART
$757 Ga´larraga et al. (26); Menzies et al. (27); Marseille et al. (28);
Marseille et al. (29)
Relative effectiveness in delaying HIV progression Deff 27% Walson et al. (9)
Fraction of HIV-positive adults with
CD4350 cells/mm3 receiving LLIN-WF
10% Authors’ assumption
Mean CD4 count of HIV-positive individuals at time of
LLIN-WF provision CD4st
500 cells/mm3 Authors’ assumption based on:
Larson et al. (32); Lugada et al. (33); Lessells et al. (34);
Govindasamy et al. (35); Akinbami et al. (36); Williams et al. (37)
Lifetime on ART
lART
33 years Mills et al. (20); Johnson et al. (21)
Estimated number of adults aged 15 years and above in
need of ART
680,000 UNAIDS (1)
ART coverage (%) 81 UNAIDS (1)
HIV prevalence (15 years and above) (%) 6.1 UNAIDS (1)
ART, antiretroviral therapy; LLIN, long-lasting insecticide-treated bednet; WF, water filter.
Table 2. Return on investment results for the intervention
providing bednets and water filters to HIV-positive adults to
delay HIV disease progression in Kenya
Scenario
Return on
investment
Base case
(Deff27%; cint$32; cART$757;
CD4st500 cells/mm
3; lART33)
11.1
Effectiveness is halved
(Deff13.5%)
4.7
Effectiveness is 50% higher
(Deff40.5%)
17.1
ART cost is halved
(cART$379)
5.5
ART cost is 50% higher
(cART$1136)
16.6
CD4st400 cells/mm
3 3.9
CD4st530 cells/mm
3 11.3
lART16.5 years 7.1
Lifetime ART costs due to new infections
not averted by ART included
5.9
ART, antiretroviral therapy; LLIN, long-lasting insecticide-treated
bednet; WF, water filter.
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annual ART cost per patient reaches cARTUS$70.
In Kenya, the LLIN-WF intervention would cost about
US$2.3 million (95% UR: 1.43.5) but would save
US$25.5 million (95% UR: 8.049.8) (discounted at 3%).
From a savings standpoint, the intervention would pre-
sent net financial savings of US$23.2 million (95% UR:
5.947.2).
Sensitivity analysis
If intervention coverage is increased (20% of HIV-positive
adults with CD4350 receive LLIN-WF), total ART
cost savings would amount to $51 million in Kenya.
If intervention coverage is decreased (5%), total ART
cost savings would amount to US$13 million in Kenya.
When the annual ART cost per patient is set at half that
previously assumed (US$379), total ART cost savings
would decrease to US$13 million in Kenya.
It is important to recognize that HIV-positive indivi-
duals who are not initiated on ART remain a potential
source of new infections. Our findings indicate that de-
ferring time to ART eligibility could potentially result
in an additional 2,800 new HIV infections not averted
by ART in Kenya (Supplementary file, Section 3.2).
This could translate to US$11 million (discounted) lifetime
ART costs in Kenya, subsequent decreased ART cost
savings of US$14 million in Kenya, and a decreased ROI
of 5.9 (95% UR: 1.913.6) (Table 2), when it is assumed
that: 70% of the newly HIV-positive individuals would
seek treatment [mean ART coverage for HIV-positive
individuals with CD4 350 cells/mm3 is currently 68%
in sub-Saharan Africa (1)]; half of these individuals would
initiate ART early [leading to a subsequent lifetime on
ART of about 33 years, which is the average of a Ugandan
estimate of 36 years (20) and a South African estimate
of 29 years (21)]; and the remaining half would initiate
ART late [leading to a subsequent lifetime on ART
of about 11 years (38)]. Further detail is given in the
Supplementary file (Section 3.2).
In spite of considerable uncertainty, the LLIN-WF
intervention still presented net financial savings even
when conservative scenarios were explored: for example,
when ART unit cost per patient-year was substantially
decreased, and when lifetime ART costs due to potential
added new infections not averted were included (Fig. 1).
Discussion
The provision of LLIN and WF to 10% of HIV-positive
adults not yet eligible for ART in sub-Saharan Africa
could potentially yield high returns on investment and
bring substantial net financial savings due to deferred time
to ART eligibility. This finding of substantial savings
in Kenya was subjected to both univariate and multivar-
iate sensitivity analyses. It was most sensitive to the
effectiveness in delaying HIV progression, the mean CD4
count at time of LLIN-WF provision, and the cost of ART
per person-year.
While a LLIN-WF intervention for HIV-positive
individuals awaiting ART initiation is an economically
attractive intervention, it may not be a favorable option
based on other considerations. Studies indicate that per-
sons receiving ART may experience a greater than 90%
reduction in HIV transmission to their partners (3942).
Hence, deferring time to ART eligibility may increase the
transmission of HIV, and accordingly, the LLIN-WF
intervention described in this analysis could result in
a number of potential new infections. Second, earlier
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Fig. 1. Comparison of the base case scenario with the two scenarios where the annual ART costs are halved to $379 and when
lifetime ART costs due to new infections not averted by ART are included. (a) Total ART cost savings versus total intervention
costs in 2011 US$ (n1,000 trials extracted from Monte Carlo simulation), and (b) distribution of return on investment (ROI)
function (n1,000 trials extracted from Monte Carlo simulation). ART, antiretroviral therapy; nnumber of simulations.
Note: the net savings frontier corresponds to the situation when total ART cost savings equals total intervention costs.
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initiation of ART can also prevent both AIDS- and
non-AIDS-related morbidity and mortality (43); and the
economic benefits including labor productivity gains
of earlier ART initiation can be substantial. Therefore,
although the ROI of a LLIN-WF intervention remains
favorable, deferring time to ART eligibility may not be
acceptable from several standpoints including a public
health or clinical standpoint, and the cost analysis offered
in this article is only one element among others into the
decision-making.
This article does not argue for prioritization of LLIN-
WF provision to HIV-positive individuals as opposed
to the general population, nor does it prioritize provision
of LLIN-WF to HIV-positive individuals as opposed
to early initiation of ART, which may provide high
returns on health. Rather, it recognizes that given the
growing demand for ART and financial resources con-
straints, early ART initiation or ART initiation for those
with CD4 350 and/or 500 is often unaffordable and
unfeasible. Given that reality, provision of LLIN-WF
to HIV-positive individuals awaiting ART initiation can
bring substantial net financial savings.
There are several limitations to this analysis. First,
the results rely heavily on data from two Kenyan studies
(9, 25). The respective contributions of LLIN and WF to
the effectiveness in deferring ART are unclear, and this
effectiveness may well change as the burden of diarrhea/
malaria varies from one setting to the next. However,
empirical data do not exist to inform a better extrapola-
tion. Our objective in this article was indeed to examine
the potential economic impact of distributing LLIN-WF
to HIV-positive individuals awaiting ART initiation,
in the context of highly resource-constrained settings.
Second, since identifying HIV-positive non-ART-eligible
individuals would require additional costs, we restricted
our analysis to the subset of HIV-positive individuals
who are aware of their HIV status. There is a lack of data
on the number of HIV-positive individuals who are aware
of their HIV status and the proportion of these that could
feasibly be reached by a LLIN-WF campaign; as such,
we chose a conservative estimate of 10% coverage of
HIV-positive individuals with CD4 cell account above
350 cells per mm3, and we assumed that only HIV-
positive ART non-eligible individuals were receiving
LLIN-WF. Furthermore, a more detailed assessment
with use of a dynamic model of HIV transmission would
help incorporate secondary HIV infections resulting from
added HIV infections not averted by ART. Finally, this
article does not estimate the intervention health benefits
(e.g. malaria, diarrhea, HIV infections averted) in order
to maximize population health per dollar spent; rather,
we indicate that the intervention brings net financial
savings when uniquely considering the HIV dimension.
LLINs and WFs are essential interventions for diarrhea
and malaria and should be made available, especially to
pregnant women and children, regardless of their effect in
delaying HIV disease progression.
The provision of LLIN and WF may be a cost-effective
and practical method for ART programs to defer ART
eligibility in the context of highly resource-constrained
environments and donor fatigue for HIV/AIDS programs.
Such an intervention could free financial and human
resources to be allocated toward HIV prevention pro-
grams and maximizing the number of individuals in critical
need of ART treatment, while focusing on deferring
time to ART eligibility among those not yet meeting
WHO ‘priority’ eligibility criteria (2). Integrated preven-
tion programs could thus contribute to the long-term
viability of ART scale-up in sub-Saharan Africa. Future
work should examine the feasibility of using limited HIV
budgets to pay for LLIN-WF when current funds are
insufficient to initiate new HIV patients on ART, and of
using malaria budgets to provide LLIN-WF in the context
of deferring time to ART eligibility.
Countries and donors must define a policy frame-
work which can maximize positive synergies between
HIV programs and health systems (44). When broad
health goals cannot be met by health systems, high-impact
interventions provided through integrated programs
are often used as an interim measure. ‘Selective primary
health care’, a strategy focused on maternal and child
health, is one example (45). Inherent in the integrated
delivery platform is the potential for it to be diversified,
taking advantage of economies of scale and scope and
combining partnerships to improve efficiency and effec-
tiveness (46). For example, in sub-Saharan Africa, LLINs
have begun to be distributed via mass immunization
campaigns (47, 48), which has enabled a scale-up in use
(49). LLIN-WF delivery could be similarly assimilated
by the existing HIV program infrastructure, including
stewardship and governance, financing, planning, delivery,
monitoring and evaluation, and demand creation (50, 51).
Development assistance for HIV/AIDS has been shown
to strengthen health systems in some countries but can
negatively impact health services where human resources
are limited (52). International donors and policy makers
should therefore weigh the costs and benefits of integration
efforts: leveraging HIV program infrastructure to launch
integrated prevention programs shows much promise,
but where such infrastructure is nascent or fragile, it may
undermine HIV programs themselves (53). Integrated
prevention programs can be an effective and cost-saving
strategy to deliver interventions and to identify individuals
with HIV or other diseases, including tuberculosis and
non-communicable diseases. The scale and rate of their
rollout should be evaluated in the context of a thorough
understanding of the strengths and weaknesses of host
health systems, as well as of the commitments of local
leaderships, international donors, and the health work-
force to particular delivery platforms (51).
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